Temporal Trends in Hospitalisations for Heart Failure.

Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic?

Age adjusted hospitalisation rates for heart failure have increased considerably throughout the western world in the 1980s and early 1990s, as documented by reports from New Zealand, the USA, Sweden, Spain, Scotland, and the Netherlands. 2 Hospitalisations account for as much as 70% of the health care budget spent on heart failure. Angiotensin converting enzyme (ACE) inhibition became the corne...

Avoidable hospitalisation rates in Singapore, 1991-1998: assessing trends and inequities of quality in primary care.

STUDY OBJECTIVES To assess avoidable hospitalisation as an indicator of quality of primary care by examining trends and gender and ethnic variations. DESIGN AND SETTING Aggregated nationwide data in Singapore from 1991 to1998 were analysed for hospitalisations for chronic diseases that are avoidable by timely, appropriate, and effective primary care: asthma, congestive heart failure, chronic ...

Statistical methodology for recurrent events, with application to major trials in heart failure

Composite outcomes are frequently adopted as primary endpoints in clinical trials as they consider fatal and non-fatal consequences of the disease under study and lead to higher event rates. Such analyses of time to first event are suboptimal for a chronic disease such as heart failure, characterised by recurrent hospitalisations, as information on repeats is ignored. We present a comparison of...

Temporal Trends in Treatment and Outcomes for Advanced Heart Failure with Reduced Ejection Fraction from 1993-2010: Findings from a University Referral Center Loh et al: Temporal Trends in Heart Failure Outcomes

Long-term use of secondary prevention medications for heart failure in Western Australia: a protocol for a population-based cohort study

INTRODUCTION Heart failure (HF) is a chronic, debilitating and progressive disease associated with high morbidity and mortality. Evidence-based medications (EBMs) are the cornerstone of management of patients with HF. In Australia, these EBMs are subsidised by the Commonwealth Government under the Pharmaceutical Benefits Scheme. Suboptimal dispensing and non-adherence to these EBMs have been ob...